Hongli Sui

Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation

Abstract Teriparatide, the only FDA-approved osteoanabolic drug for osteoporosis, suffers from poor metabolic stability and requires frequent subcutaneous injections, leading to suboptimal patient compliance. To find optimized teriparatide derivatives, we herein report an iterati...